| Literature DB >> 28035083 |
Sungjin Lee1, Yoon Hee Chung2, Choongho Lee1.
Abstract
Viruses continue to evolve a new strategy to take advantage of every aspect of host cells in order to maximize their survival. Due to their central roles in transducing a variety of transmembrane signals, GPCRs seem to be a prime target for viruses to pirate for their own use. Incorporation of GPCR functionality into the genome of herpesviruses has been demonstrated to be essential for pathogenesis of many herpesviruses-induced diseases. Here, we introduce US28 of human cytomegalovirus (HCMV) as the beststudied example of virally-encoded GPCRs to manipulate host GPCR signaling. In this review, we wish to summarize a number of US28-related topics including its regulation of host signaling pathways, its constitutive internalization, its structural and functional analysis, its roles in HCMV biology and pathogenesis, its proliferative activities and role in oncogenesis, and pharmacological modulation of its biological activities. This review will aid in our understanding of how pathogenic viruses usurp the host GPCR signaling for successful viral infection. This kind of knowledge will enable us to build a better strategy to control viral infection by normalizing the virally-dysregulated host GPCR signaling.Entities:
Keywords: Antiviral target; Chemokine receptor; G protein-coupled receptor; Human cytomegalovirus; US28; Virally-encoded G protein-coupled receptor
Year: 2017 PMID: 28035083 PMCID: PMC5207464 DOI: 10.4062/biomolther.2016.208
Source DB: PubMed Journal: Biomol Ther (Seoul) ISSN: 1976-9148 Impact factor: 4.634
Fig. 1.Schematic diagram of general GPCR signaling pathways and key molecular players. Signaling pathways were drawn based on specific functions of four different members of activated Gα and Gβγ complex upon ligand binding. Major effector proteins mediating downstream signaling were also depicted. Acronyms used are as follows. GDP: guanosine diphosphate, GTP: guanosine triphosphate, cAMP: cyclic adenosine monophosphate, PKA: protein kinase A, PLCβ: phospholipase C beta, DAG: diacyl glycerol, IP3: inositol triphosphates, PI3K: phosphoinositide 3-kinase.
Human herpesvirus-encoded GPCRs
| Virus | GPCRs | Ligand | G protein-coupling | Activated signaling pathways |
|---|---|---|---|---|
| KSHV | ORF74 |
Endogenous agonists: CXCL1, CXCL2, CXCL3, mouse CXCL1, mouse CXC2 Endogenous neutral agonists: CXCL4, CXCL5, CXCL7, CXCL8 Endogenous inverse agonists: CXCL6, CXCL10, CXCL12, viral CXCL2, mouse CXCL10, CCL1 and CCL15 |
Gaq, Gai, Ga12/13 |
Constitutive and ligand-induced: RAC1, PLC, PKC, calcineurin, PI3Kγ, AKT, JNK–SAPK, LYN–SRC, GSK3, JAK2–STAT3, HIF1a |
| EBV | BILF1 |
Not known |
Gai |
Constitutive: NF-κB, CREB72,73 |
| HCMV | US28 |
Endogenous agonists: CCL2, CCL3, CCL4, CCL5, CCL7, CCL11, CCL13, CCL26, CCL29 CX3CL1 Small-molecule inverse agonists |
Gaq, Gai/o, Ga12/13 |
Constitutive: PLC, NF-κB, CREB, NFAT, SRF, STAT3, TCF–LEF Ligand-induced: CCL2, CCL5 via Gai/o, calcium, SRC–FAK, MAPK via Ga12/13, RHOA136,172 |
| UL33 |
Not known |
Gaq, Gai, Gas |
Constitutive: PLC, CREB | |
| US27 |
Not known |
Not known |
Few US27 changes in cellular gene expression have been observed | |
| UL78 |
Not known |
Not known |
Not constitutively active, signaling pathways not known |
Fig. 2.Schematic diagram of GPCR signaling pathways activated by HCMV US28 receptor upon endogenous ligand binding. Agonist-dependent signaling pathways by US28 were drawn based on specific functions of two different members of activated Gα and Gβγ complex upon ligand binding. Major effector proteins mediating downstream signaling, upregulated calcium concentration and an activated transcription factor were also depicted. Acronyms used are as follows. Rho: Ras homolog gene family member, FAK: focal adhesion kinase, PLCβ: phospholipase C beta, NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells, 6HP: hexapeptide. VUF2274 is an inverse agonist for US28.
Fig. 3.Schematic diagram of GPCR signaling pathways activated by HCMV US28 receptor without any ligand binding. Agonist-independent signaling pathways by US28 were drawn based on specific functions of two different members of activated Gα and Gβγ complex without ligand binding. Major effector proteins mediating downstream signaling and activated transcription factors were also depicted. Acronyms used are as follows. AC: adenylyl cyclase, PKA: protein kinase A, SERCA: sarcoplasmic reticulum calcium ATPase, NFAT: nuclear factor of activated T-cells, NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells, IL-6: interleukin 6, JAK1: Janus kinase 1, STAT3: signal transducer and activator of transcription 3, COX: cyclic oxygenase, VEGF: vascular epidermal growth factor, DRY: dry motif. VUF2274 is an inverse agonist for US28.
Fig. 4.Schematic diagram of internalization and recycling of HCMV US28. Major effector proteins involved in internalization and recycling of HCMV US28 upon chemokine binding were also depicted. Acronyms used are as follows. GDP: guanosine diphosphate, GTP: guanosine triphosphate, GRK: GPCR-associated kinase.
Summary of small molecule US28 modulators. Their groups, names of compounds, types, mechanisms, EC50 values, chemical structures, and references were also included
| Group | Compound | Type | Mechanism | EC50 (μm) | Chemical structure | Reference |
|---|---|---|---|---|---|---|
| VUF2274 | 5-(4-(4-chlorophenyl)-4-hydroxy-piperidin-1-yl)-2,2-diphenylpentanenitrile | Inverse agonist | Constitutive PLCb activation | 4.5 |
| |
| Methiothepin | Antagonist | CCL5 binding | 0.4 |
| ||
| Hydroisoquinoline | 3-(2-hydroxyethyl)-3-methyl-2-phenyl03,4-dihydroisoquinolin-1(2H)-one | Inverse agonist | Constitutive PLCb activation | 1.5 |
| |
| N-(2-aminoethyl)-N-((3-methyl-1-oxo-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)decanamide | Inverse agonist | Constitutive PLCb activation | 1.5 |
| ||
| 3-(2-hydroxyethyl)-3-methyl-2-phenyl-3,4-dihydroisoquinolin-1(2H)-one | Inverse agonist | Constitutive PLCb activation | 1.0 |
| ||
| (3-methyl-1-oxo-2-(2-phenylacetyl)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl 2-phenylacetate | Inverse agonist | Constitutive PLCb activation | 3.4 |
| ||
| Biphenyl amide | Decanoic acid (4′-chloro-6-methoxybiphen-3-ylmethyl)-(2-dimethylaminoethyl) amide | Inverse agonist | Constitutive PLCb activation | 2.4 |
| |
| Flavonoid | 5-(benzyloxy)-2-(5-bromo-2-methoxyphenyl)-4H-chromen-4-one | Inverse agonist | Constitutive PLCb activation | 3.5 |
| |
| Other | (4-(4-chlorophenyl)-1-(4,4-diphenylbutyl)piperidin-4-yl) | Antagonist | CCL5 binding | 3.6 |
|